CabaCy—evaluating Cabazitaxel efficaCy by patterns of treatment and disease in metastatic castration resistant prostate cancer (mCRPC) patients: a 5 years, “Real Life”, mono-institutional experience
- 1 October 2017
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 28 (suppl_6) , vi21-vi22